<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02535767</url>
  </required_header>
  <id_info>
    <org_study_id>14-14495</org_study_id>
    <nct_id>NCT02535767</nct_id>
  </id_info>
  <brief_title>Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali</brief_title>
  <acronym>PQSAFETY</acronym>
  <official_title>Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Malaria Research and Training Center, Bamako, Mali</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the highest tolerable dose of primaquine within&#xD;
      0.75 mg/kg. A tolerable dose is defined as one in which:&#xD;
&#xD;
        -  Two or fewer participants (&lt; 30%) experience hemolysis;&#xD;
&#xD;
        -  No participant experiences a drug-related serious adverse event; and&#xD;
&#xD;
        -  No participant requires a blood transfusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: The purpose of this study is to determine the highest tolerable dose of primaquine&#xD;
      within 0.75 mg/kg. A tolerable dose is defined as one in which:&#xD;
&#xD;
        -  Two or fewer participants (&lt; 30%) experience hemolysis;&#xD;
&#xD;
        -  No participant experiences a drug-related serious adverse event; and&#xD;
&#xD;
        -  No participant requires a blood transfusion.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  This is an open-label, phase 2, dose-adjustment study.&#xD;
&#xD;
        -  The initial primaquine dose will be 0.40 mg/kg. Subsequent dose groups will be selected&#xD;
           depending on the occurrence of adverse events in the previous dose group. Once the&#xD;
           highest tolerable dose in G6PD-deficient (G6PDd) individuals is established, a control&#xD;
           group of G6PD normal malaria-free men will be enrolled and evaluated under the highest&#xD;
           tolerable dose of primaquine.&#xD;
&#xD;
      Study Population:&#xD;
&#xD;
        -  Malian men aged 18-50 years without malaria infection.&#xD;
&#xD;
        -  The majority of study participants will be G6PDd.&#xD;
&#xD;
      Study Size: This study will enroll 7 participants per dose group. If all dose groups are&#xD;
      tested, this study will enroll approximately 28 participants.&#xD;
&#xD;
      Study visit and duration:&#xD;
&#xD;
        -  Each participant will be followed for 28 days.&#xD;
&#xD;
        -  Participants will be evaluated for hemolysis and adverse events on Days 1-10, 14, and 28&#xD;
           following their assigned primaquine dose.&#xD;
&#xD;
      Primary objective:&#xD;
&#xD;
      To measure the change in hemoglobin among G6PD deficient west-African men following a single&#xD;
      low-dose of primaquine not to exceed 0.75 mg/kg.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        1. To measure the occurrence of adverse events, graded by severity, at each primaquine dose&#xD;
           among G6PD deficient men&#xD;
&#xD;
        2. To measure the occurrence of markers of acute hemolytic anemia (AHA), at each primaquine&#xD;
           dose among G6PD deficient men. AHA markers will include:&#xD;
&#xD;
             -  Absolute and fractional change in hemoglobin on day 7 vs. baseline&#xD;
&#xD;
             -  Urine color&#xD;
&#xD;
             -  Reticulocyte count&#xD;
&#xD;
             -  Bilirubin (both total and direct)&#xD;
&#xD;
             -  Methemoglobin concentration&#xD;
&#xD;
             -  Development of physical signs or symptoms of hemolytic anemia&#xD;
&#xD;
        3. To compare the change in hemoglobin, frequency and severity of adverse events, and&#xD;
           occurrence of markers of AHA between G6PD deficient and non-deficient participants&#xD;
           receiving the highest tolerable primaquine dose&#xD;
&#xD;
        4. To measure G6PD enzyme activity (semiquantitative testing, U / gHb)&#xD;
&#xD;
        5. To measure the pharmacokinetics of primaquine, carboxyprimaquine, and other metabolites&#xD;
           according to plasma concentrations.&#xD;
&#xD;
        6. To genotype participant blood samples for cytochrome P450 2D6 (CYP2D6) single nucleotide&#xD;
           polymorphisms (SNPs), to determine if potential hemolysis in G6PDd individuals is&#xD;
           affected by CYP2D6 metabolizer status (e.g. weak metabolizers and/or intermediate&#xD;
           metabolizers)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome: the change in hemoglobin concentration from baseline levels following a single low-dose of primaquine not to exceed 0.75 mg/kg.</measure>
    <time_frame>Between day 0 and day 10.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the occurrence of adverse events, graded by severity, at each primaquine dose among G6PD deficient men</measure>
    <time_frame>Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, and 28</time_frame>
    <description>Severity:&#xD;
= mild&#xD;
= moderate&#xD;
= severe&#xD;
= life threatening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the occurrence of absolute and fractional change in hemoglobin concentration (g/dL) on day 7 vs. baseline at each primaquine dose among G6PD deficient men, in comparison with G6PD normal men</measure>
    <time_frame>Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure the occurrence of reticulocytosis (by microscopic quantification of reticulocytes stained with brilliant cresyl blue / 1,000 RBCs) on each day of followup, at each primaquine dose, among G6PD deficient men, in comparison with G6PD normal men</measure>
    <time_frame>Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To monitor methemoglobin levels (%) on each day of followup, at each primaquine dose among G6PD deficient men, in comparison with G6PD normal men</measure>
    <time_frame>Days 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 14, and 28</time_frame>
    <description>Use of a Masimo Rad-57 pulse oximeter that measures methemoglobin levels non-invasively, based on absorption of light through the fingertip.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine G6PD enzyme activity (semiquantitative testing, U/g Hb)</measure>
    <time_frame>Day 0</time_frame>
    <description>Semiquantitative testing will be performed on frozen blood samples to determine G6PD activity on day of enrolment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) for primaquine</measure>
    <time_frame>Hours 1, 2, 4, 6, 8, and 24 after primaquine administration</time_frame>
    <description>Pharmacokinetic analysis of plasma concentration of primaquine at all sampled timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal concentration (Cmax) for primaquine</measure>
    <time_frame>Hours 1, 2, 4, 6, 8, and 24 after primaquine administration</time_frame>
    <description>Pharmacokinetic analysis of plasma concentration of primaquine at all sampled timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) for carboxyprimaquine</measure>
    <time_frame>Hours 1, 2, 4, 6, 8, and 24 after primaquine administration</time_frame>
    <description>Pharmacokinetic analysis of plasma concentration of carboxyprimaquine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal concentration (Cmax) for carboxyprimaquine</measure>
    <time_frame>Hours 1, 2, 4, 6, 8, and 24 after primaquine administration</time_frame>
    <description>Pharmacokinetic analysis of plasma concentration of carboxyprimaquine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) for select minor metabolites of primaquine</measure>
    <time_frame>Hours 1, 2, 4, 6, 8, and 24 after primaquine administration</time_frame>
    <description>Pharmacokinetic analysis of plasma concentration of metabolites of primaquine, exact metabolites to be determined by ongoing in vivo studies (including 5-hydroxyprimaquine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal concentration (Cmax) for select minor metabolites of primaquine</measure>
    <time_frame>Hours 1, 2, 4, 6, 8, and 24 after primaquine administration</time_frame>
    <description>Pharmacokinetic analysis of plasma concentration of metabolites of primaquine, exact metabolites to be determined by ongoing in vivo studies (including 5-hydroxyprimaquine)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytochrome P450 (CYP) 2D6 genotyping</measure>
    <time_frame>Day 0</time_frame>
    <description>To determine whether a correlation between CYP 2D6 metabolism (weak metabolizer, intermediate metabolizer, normal metabolizer, ultrarapid metabolizer) and hemolysis exists.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>A: 0.40 mg/kg PQ G6PDd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.40 mg/kg of primaquine (as a single dose) in G6PD-deficient individuals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: PQ in G6PDd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of primaquine in G6PD-deficient men, exact dose to be decided by DSMB based on findings in previous dose group. The minimum change in dose from the last study dose is 0.05 mg/kg, and the maximum change is 0.20 mg/kg of primaquine). Dose is not to exceed 0.75 mg/kg primaquine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: PQ in G6PDd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of primaquine in G6PD-deficient men, exact dose to be decided by DSMB based on findings in previous dose group. The minimum change in dose from the last study dose is 0.05 mg/kg, and the maximum change is 0.20 mg/kg of primaquine). Dose is not to exceed 0.75 mg/kg primaquine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D: PQ G6PDn</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of primaquine in G6PD-normal men, at the highest tolerable dose determined by the DSMB, from previous dose groups.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Primaquine</intervention_name>
    <description>A single low dose of primaquine will be crushed and dissolved in water, and administered in weight-based doses.</description>
    <arm_group_label>A: 0.40 mg/kg PQ G6PDd</arm_group_label>
    <arm_group_label>B: PQ in G6PDd</arm_group_label>
    <arm_group_label>C: PQ in G6PDd</arm_group_label>
    <arm_group_label>D: PQ G6PDn</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males ages 18- 50 (inclusive)&#xD;
&#xD;
          -  Ability to swallow oral medication&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
          -  Willing and able to participate in the study for 28 days&#xD;
&#xD;
        For the G6PDd participants:&#xD;
&#xD;
          -  G6PDd defined by Carestart 3 rapid diagnostic test or&#xD;
&#xD;
          -  The OSMMR2000 G6PD qualitative test&#xD;
&#xD;
        For the G6PDn participants:&#xD;
&#xD;
          -  G6PDn defined by Carestart 3 rapid diagnostic test or&#xD;
&#xD;
          -  The OSMMR2000 G6PD qualitative test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Moderate to severe anemia (Hb &lt; 10 g/dL)&#xD;
&#xD;
          -  Malaria infection by blood smear&#xD;
&#xD;
          -  Individuals with known positive HIV test&#xD;
&#xD;
          -  Individuals with known positive hepatitis B test.&#xD;
&#xD;
          -  Known allergy to study drugs&#xD;
&#xD;
          -  Current use of medication (for tuberculosis, HIV, or any drugs that have hemolytic&#xD;
             potential in G6PDd individuals including sulphonamides, dapsone, nitrofurantoin,&#xD;
             nalidixic acid, ciprofloxacin, methylene blue, toluidine blue, phenazopyridine, and&#xD;
             co-trimoxazole)&#xD;
&#xD;
          -  The individual is unwilling to abstain from the ingestion of grapefruit-containing&#xD;
             products from 72 hours prior to the start of dosing until the study is complete&#xD;
&#xD;
          -  Use of antimalarials within 2 weeks before contact with the study team as reported by&#xD;
             the patient&#xD;
&#xD;
          -  History of blood transfusion or a bleed of &gt; 500 mLs within the last 3 months, as&#xD;
             reported by the patient&#xD;
&#xD;
          -  Reported history of high alcohol intake (&gt; 14 units per week, each unit is equivalent&#xD;
             to 10 g of alcohol (1 glass of wine or 1 bottle of beer or one shot of distilled&#xD;
             spirits), within 6 months of study as reported by the patient&#xD;
&#xD;
          -  Reported use of illicit drugs (marijuana, heroin, cocaine, methamphetamine) or&#xD;
             dependence within 6 months of study, as reported by the patient&#xD;
&#xD;
          -  Participants who vomit within 1 hour after administration of primaquine (will be&#xD;
             removed from the analysis and will not count towards the total sample size, though&#xD;
             they will be followed as any other enrolled individual)&#xD;
&#xD;
          -  Already enrolled in this study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Gosling, PhD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Malaria Research and Training Centre</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mali</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>August 7, 2015</study_first_submitted>
  <study_first_submitted_qc>August 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <last_update_submitted>February 2, 2017</last_update_submitted>
  <last_update_submitted_qc>February 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primaquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primaquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

